“…213−224 These structures include two noncanonical amino acids bearing all-carbon quaternary stereocenters, 213 a trio of organic semiconductors solved at ultrahigh resolution (one of which is depicted in Figure 9E), 54 a family of electron-deficient expanded helicenes, 216 a pentacyclic indole-derived ester, 217 and a synthetic mimic of the cuboidal subunit in the oxygen-evolving complex of photosystem II. 220 Finally, 3D ED has also tackled a bevy of small-molecule active pharmaceutical ingredients (APIs), including carbamazepine, 200,225 niacin (nicotinic acid), 225 bismuth subgallate, 226 ibuprofen, 200 ethisterone, 200 progesterone, 200 biotin, 200 paracetamol (acetaminophen), 143,199,200 cimetidine, 227 loratadine, 125 sofosbuvir, 143 ramelteon, 228 tolvaptan, 228 olanzapine, 229 epicorazine A, 144 dehydrocurvularin, 144 metaxalone, 230 teniposide, 231 remdesivir, 232 and indomethacin. 126 Because many APIs exist natively as microcrystalline powders, 3D ED could potentially revolutionize solid-state structure determination in the pharmaceutical industry, 231,233 where size-limited single-crystal XRD is currently the gold standard.…”